Short description
Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.
Description
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen-presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic.
Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology, and immuno-oncology.
Last funding
Cannot Access
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Cambridge, Massachusetts, United States, North America
Founded on
January 1, 2014
Exited on
January 2, 2018
Went public on
January 2, 2018
Stock symbol
CUE
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$7890 - 12340
Sign in for full access
Investors
Cannot Access
Sign in for full access
Founders
Rodolfo Chaparro, Ronald Seidel